Dr. Linda Vahdat is seeking men and women with HER2+ metastatic breast cancer to participate in a research study.
The purpose of this study is to evaluate the effectiveness of margetuximab in combination with standard of care chemotherapies in the setting of patients with metastatic HER2+ breast cancer who have received prior treatment with trastuzumab, pertuzumab, and adotrastuzumab.
To see learn more and see if you qualify to participate [go]
Dr. Linda Vahdat speaks with MDLinx about copper depletion research in triple negative breast cancer.
“Copper is an interesting element. It’s involved in multiple biologic processes, which are important for tumor progression both within the tumor itself and within the tumor microenvironment. In the tumor microenvironment, it facilitates tumors doing their bad things,” explained lead author Linda T. Vahdat, MD, MBA, professor of medicine, Weill Cornell Medicine and NewYork-Presbyterian, and director of the Breast Cancer Research Program and co-leader of the Breast Cancer Program, Meyer Cancer Center, New York, NY.
To learn more and see the original article and interview video [go]
Dr. Linda Vahdat is seeking volunteers for a new research study in triple negative breast cancer.
This clinical trial is for women with metastatic triple-negative breast cancer (mTNBC). This means that the three most common types of receptors (estrogen, progesterone, and human epidermal growth factor [HER2]) known to fuel most breast cancer growth are not present in their cancer.
The purpose of this study is to evaluate the effectiveness and safety of eribulin mesylate (“eribulin”) in combination with pembrolizumab in metastatic (spread of cancer from one part of body to another) triple-negative breast cancer.
For more information visit our website
Vahdat says the hope among oncologists for glembatumumab vedotin is that the treatment can deliver a much higher dose of drug to the tumor than you normally would be able to, and directly into the tumor cell.
